Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-2: Weekly eloralintide in adults with overweight or obesity and type 2 diabetes
CTR20260922Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of eloralintide in obesity, Overweight, type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Jan 2026; status: active.
02
Drugs
eloralintide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20260922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260922.